関連する実験動画
Updated: Sep 9, 2025

10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
11.2K
Xanthoma Disseminatumの患者におけるクラドリビンの長期的治療結果
Ananya Sharma1, Neha Taneja, Ritu Sharma
1Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Indian dermatology online journal
|August 29, 2025
まとめ
クラドリビン (2- クロロロデオキシアデノシンまたは2CdA) は,全身性キサントーマ発散を6人の患者で効果的に治療し,有意な改善を示した. 大半の患者は長期フォローアップで 副作用が最小限にとどまった.
科学分野:
- 血液学
- 腫瘍学
- 皮膚科
背景:
- Xanthoma disseminatum (XD) は,全身的な症状を持つ希少なヒスティオサイト性疾患である.
- XDの全身的な関与については,限られた治療法があります.
研究 の 目的:
- 系統性キサントーマ発散の患者におけるクラドリビン (2- クロロロデオキシアデノシンまたは2CdA) の有効性と安全性を評価する.
主な方法:
- 3〜12サイクル毎月クラドリビンを投与した全身性XD患者6人のケースシリーズ.
- 治療反応の評価,長期追跡,有害事象
主要な成果:
- 治療終了時に63. 3%の改善を達成し,フォローアップ時に75%に増加しました (2.1 ± 1.6年).
- 頭蓋内および喉内病変の有意な改善が観察されました.
- クラドリビンはよく耐えており,患者の50%は一時的な白血病でした.
結論:
- クラドリビンは,全身性キサントーマ発散に対する有意な有効性と耐容性を示しています.
- この希少な病気の治療には 有望な治療法です
関連する概念動画
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K

